{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "CNY", "exchange": "SHH", "shortName": "HINOVA PHARMACEUTICALS INC", "longName": "Hinova Pharmaceuticals Inc.", "messageBoardId": "finmb_592928101", "exchangeTimezoneName": "Asia/Shanghai", "exchangeTimezoneShortName": "CST", "gmtOffSetMilliseconds": 28800000, "market": "cn_market", "esgPopulated": false, "marketState": "POSTPOST", "regularMarketChangePercent": 5.761122, "regularMarketPrice": 70.31, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -2.91, "sharesOutstanding": 99015600, "bookValue": 16.531, "fiftyDayAverage": 62.7298, "fiftyDayAverageChange": 7.5801964, "fiftyDayAverageChangePercent": 0.12083884, "twoHundredDayAverage": 47.35075, "twoHundredDayAverageChange": 22.959248, "twoHundredDayAverageChangePercent": 0.48487613, "marketCap": 6961786368, "priceToBook": 4.253221, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.3 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1649727000000, "priceHint": 2, "regularMarketChange": 3.8299942, "regularMarketTime": 1683874802, "regularMarketDayHigh": 71.6, "regularMarketDayRange": "65.52 - 71.6", "regularMarketDayLow": 65.52, "regularMarketVolume": 968777, "regularMarketPreviousClose": 66.48, "bid": 70.31, "ask": 70.76, "fullExchangeName": "Shanghai", "financialCurrency": "CNY", "regularMarketOpen": 65.88, "averageDailyVolume3Month": 943279, "averageDailyVolume10Day": 978249, "fiftyTwoWeekLowChange": 40.399998, "fiftyTwoWeekLowChangePercent": 1.3507187, "fiftyTwoWeekRange": "29.91 - 78.77", "fiftyTwoWeekHighChange": -8.459999, "fiftyTwoWeekHighChangePercent": -0.10740129, "fiftyTwoWeekLow": 29.91, "fiftyTwoWeekHigh": 78.77, "trailingAnnualDividendRate": 0.0, "symbol": "688302.SS"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Building 1, Rongyao Building, No. 5", "address2": "No. 2, 3, 4th Floor Keyuan South Road High-tech Zone", "city": "Chengdu", "zip": "610041", "country": "China", "phone": "86 28 8505 8465", "fax": "86 28 8505 8465", "website": "https://www.hinovapharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Hinova Pharmaceuticals Inc. engages in the development and production of drugs in the therapeutic areas of tumors and metabolic diseases. It develops drugs based on technology platforms, such as deuterium and PROTAC. The company's products in pipeline include HC-1119, a product in Phase III clinical trials with castration resistant prostate cancer indications; HP501, a product in Phase II clinical trials for the treatment of hyperuricemia and gout; HP558, a product that completed Phase I clinical trials to treat various advanced cancers; and HP518, an oral PROTAC drug in pre-clinical stage with a focus on to solve the drug resistance of AR-mutated prostate cancer. It serves customers in China, the United States, Japan, Europe, and internationally. The company was founded in 2013 and is headquartered in Chengdu, China. Hinova Pharmaceuticals Inc. is a subsidiary of Haisco Pharmaceutical Group Co., Ltd.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Yuanwei  Chen", "age": 59, "title": "Chairman  & Gen. Mang.", "yearBorn": 1963, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}